Telavancin

From Wikipedia, the free encyclopedia

Telavancin
Identifiers
CAS number	[372151-71-8]
PubChem	3081362
MeSH	Telavancin
Properties
Molecular formula	C80H106Cl2N11O27P
Molar mass	1755.63 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Telavancin is a bactericidal lipoglycopeptide under trial for use in MRSA or other Gram-positive infections.

On October 19, 2007, the US Food and Drug Administration issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008. ^[1]

[edit] References

[edit] External links

• Theravance, Inc.

v • d • e Antibacterials for systemic use: others (J01X) Glycopeptide Vancomycin (Oritavancin, Telavancin) - Teicoplanin (Dalbavancin) Polymyxins Colistin - Polymyxin B Steroid antibacterials Fusidic acid Imidazole derivatives Metronidazole - Tinidazole - Ornidazole Nitrofuran derivatives Nitrofurantoin - Nifurtoinol Other -mycin (Fosfomycin, Spectinomycin, Daptomycin, Hitachimycin) Xibornol - Clofoctol - Methenamine - Iclaprim - Mandelic acid - Nitroxoline - Linezolid